Mounjaro tablets in the UK: what the question is really asking

Why 'Mounjaro tablets' isn't a search with a simple yes-or-no answer

The phrase turns up a lot, and that's understandable. Tablets feel familiar. Injections feel like a step up. So people search for a tablet version of tirzepatide hoping one exists, or wondering whether something they've read about online is real. If you want a thorough look at whether you can get Mounjaro tablets, the short answer is that it isn't available yet, at least not in any licensed form. The medicines regulator that matters here is the MHRA, and as things stand, tirzepatide has no licensed oral form anywhere in the world. What you may have read about are early-phase trials of an oral tirzepatide molecule; those are research, not products you can be prescribed.

That matters because the UK only permits prescribing of medicines with a valid marketing authorisation for the relevant indication. Any seller offering 'tirzepatide tablets' or 'Mounjaro pills' in the UK is either describing a different medicine or selling something unlicensed. Neither is a route worth taking. The Mounjaro KwikPen, by contrast, has full MHRA approval for weight management in adults with a BMI of 30 or above, or from 27 with at least one weight-related health condition.

So the real decision the question points toward is: does the injection put you off enough that you want to explore a licensed oral alternative, or are you open to the injection once you understand what it involves? Both are reasonable starting points for a conversation with a prescriber.

What the only licensed oral GLP-1 weight-loss tablet in the UK actually is

On 11 June 2026 the MHRA approved the Wegovy tablet (oral semaglutide co-formulated with an absorption enhancer) making the UK the first country in Europe to license an oral GLP-1 medicine for weight management. This is not the same as Rybelsus, which is also oral semaglutide but licensed only for type 2 diabetes at different doses. The Wegovy tablet is a distinct product with its own dosing schedule for weight loss.

The titration runs from 1.5mg daily up through 4mg and 9mg to a 25mg maintenance dose, with at least a month at each level. In the OASIS 4 phase-3 trial (64 weeks, 307 adults with obesity or overweight plus at least one weight-related condition), participants lost an average of around 13.6% of their body weight compared with roughly 2.4% on placebo; among those who stayed fully adherent throughout, average weight loss reached approximately 16.6%. You can read more about the MHRA's approval and the supporting evidence on the oral GLP-1 weight-loss tablet page.

One practical advantage worth knowing: the Wegovy tablet needs no refrigeration. It's taken first thing in the morning on an empty stomach with a small amount of plain water, then you wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines. For people who travel frequently or simply dislike the idea of keeping medicine in the fridge, that's a meaningful difference from the injection.

How the Mounjaro injection compares if tablets aren't the priority

If the reason for searching 'mounjaro tablets' is curiosity rather than needle aversion, it's worth knowing what the injection actually involves. The KwikPen delivers a single dose once a week. Most people choose the abdomen, thigh or upper arm, rotating sites. The pen is pre-filled and pre-set, you don't draw up a dose or adjust anything yourself. Many patients say it becomes unremarkable within a few weeks, comparable in effort to any other weekly habit.

On results, the clinical evidence for the injection is substantial. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, tirzepatide at its highest dose produced an average body-weight reduction of around 20 to 21% over 72 weeks in adults with obesity. In a head-to-head comparison with semaglutide 2.4mg injection (SURMOUNT-5, NEJM 2025), tirzepatide produced greater average weight loss. The mechanism behind that (activating both GIP and GLP-1 receptors rather than one) is the reason most researchers point to for the larger effect.

The injection does require cold storage between 2°C and 8°C. Treatment starts at 2.5mg, a dose designed to let your body adjust rather than to produce weight loss immediately; your prescriber manages the titration from there. Common side effects are gastrointestinal: nausea, loose stools, constipation or indigestion, most noticeable in the first days after starting or increasing a dose and usually settling with time. The NHS tirzepatide page covers the full side-effect profile in plain language.

Which medicine is right for you, and how that decision gets made

The honest answer is that neither medicine is universally better. The Mounjaro injection has more trial data, a longer clinical track record, and stronger average weight-loss figures across the published evidence. The Wegovy tablet is newer, requires no injection and no cold chain, but has a smaller evidence base so far and a different mechanism. A few practical questions tend to drive the decision: how strongly do you feel about injections, how does your week look for morning timing (some people find the tablet's 30-minute pre-meal window easier on a Monday, harder during holidays or shift work), and does your medical history favour one approach over the other.

Those questions belong in a clinical consultation, not a search results page. If you're weighing the options (and cost is part of that) the cost comparison for Mounjaro in the UK gives an honest picture of what private treatment involves. If you'd like our prescribers to assess your situation, you can check your eligibility without any obligation. Every consultation at nume is reviewed personally by a GPhC-registered Independent Prescriber the same day.